Innate Pharma S.A. (IPHA) PT Raised to $16 at Citi
Tweet
Share
E-mailGet Alerts IPHA Hot Sheet
Price: $1.87 -0.53%
Rating Summary:
5 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 5 | New: 34
Rating Summary:
5 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 5 | New: 34
Join SI Premium – FREE
Citi analyst Yigal Nochomovitz raised the price target on Innate Pharma S.A. (NASDAQ: IPHA) to $16.00 (from $14.00) while maintaining a Buy rating.
You May Also Be Interested In
- Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update
- Destination XL Group (DXLG) PT Lowered to $1.25 at DA Davidson on Weak Consumer Spending
- Visual Photonics Epitaxy Co Ltd (2455:TT) PT Raised to NT$846 at Macquarie
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
